Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open indications, Gilead Sciences (GILD) buys Kite Pharma in all cash deal

August 28, 2017 7:08am

GILD will pay $180 per share, a 29% premium

The real issue – has the future of all these cell therapy arrived?

We have all been waiting for a sign; has it come or is this just a glimpse of the future?

Preview RMi's morning call. To get the pre-open briefing, plus daily access to the happenings and realities of “our” universe - SUBSCRIBE!

Pre-open indications: 3 BUY and 3 SELLs

Critical pre-market indications ahead of “our” universe’s open!

Lower open expected

Dow futures are DOWN -0.09% and NASDAQ futures are DOWN -0.07%

U.S. stock index futures pointed to a lower open on Monday, as investors turned their attention to how the oil market was performing after Hurricane Harvey wreaked havoc in the U.S. over the weekend.

European markets were lower as the euro hit a two-and-a-half year high and investors kept a close eye on the moves in oil.

Asian indexes came under pressure after the euro soared following Friday speeches from top central bankers. Oil markets, meanwhile, digested the impact of Hurricane Harvey.

Data docket: advance economic indicators are set to be released at 8.30 a.m. ET, followed by the Dallas Fed's Texas Manufacturing Outlook survey, due out at 10.30 a.m. E

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.